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Abstract 
Background: Plasmodium vivax 48/45 protein is expressed on the surface of gametocytes/gametes and plays a key 
role in gamete fusion during fertilization. This protein was recently expressed in Escherichia coli host as a recombinant 
product that was highly immunogenic in mice and monkeys and induced antibodies with high transmission‑block‑
ing activity, suggesting its potential as a P. vivax transmission‑blocking vaccine candidate. To determine sequence 
polymorphism of natural parasite isolates and its potential influence on the protein structure, all pvs48/45 sequences 
reported in databases from around the world as well as those from low‑transmission settings of Latin America were 
compared.
Methods: Plasmodium vivax parasite isolates from malaria‑endemic regions of Colombia, Brazil and Honduras 
(n = 60) were used to sequence the Pvs48/45 gene, and compared to those previously reported to GenBank and 
PlasmoDB (n = 222). Pvs48/45 gene haplotypes were analysed to determine the functional significance of genetic 
variation in protein structure and vaccine potential.
Results: Nine non‑synonymous substitutions (E35K, Y196H, H211N, K250N, D335Y, E353Q, A376T, K390T, K418R) and 
three synonymous substitutions (I73, T149, C156) that define seven different haplotypes were found among the 282 
isolates from nine countries when compared with the Sal I reference sequence. Nucleotide diversity (π) was 0.00173 
for worldwide samples (range 0.00033–0.00216), resulting in relatively high diversity in Myanmar and Colombia, and 
low diversity in Mexico, Peru and South Korea. The two most frequent substitutions (E353Q: 41.9 %, K250N: 39.5 %) 
were predicted to be located in antigenic regions without affecting putative B cell epitopes or the tertiary protein 
structure.
Conclusions: There is limited sequence polymorphism in pvs48/45 with noted geographical clustering among Asian 
and American isolates. The low genetic diversity of the protein does not influence the predicted antigenicity or pro‑
tein structure and, therefore, supports its further development as transmission‑blocking vaccine candidate.
© 2016 Vallejo et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Malaria is an infectious parasitic disease caused by the 
genus Plasmodium which is transmitted by bites of 
infected Anopheles mosquitoes. Plasmodium falcipa-
rum and Plasmodium vivax are the two most common 
malaria parasites in humans, however differing in their 
clinical presentation and geographic distribution. Plas-
modium falciparum causes the most severe symptoms 
and higher mortality, mainly among children under 
5  years of age in Africa. Plasmodium vivax generally 
causes milder disease, is significantly less life-threaten-
ing [1] and is widely distributed in the Middle East, Asia, 
the Western Pacific, and Central and South America [2]. 
Despite global efforts to control malaria transmission 
resulting in a significant decrease in global incidence 
during the last decade, it continues to challenge public 
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health systems, particularly in tropical countries. Cur-
rent global malaria control strategies will greatly ben-
efit from the development of an effective vaccine that 
interrupts malaria transmission among individuals of 
endemic communities [3, 4].
Proteins expressed by parasite sexual stages, namely 
gametocytes/gametes, could induce effective immune 
responses in the human host that would prevent gamete 
fertilization and zygote formation when ingested by the 
mosquito during a blood meal [5].
Plasmodium Ps48/45 proteins are expressed by male 
and female gametocytes/gametes during the parasite 
maturation process, and are therefore classified as pre-
fertilization antigens [6]. These proteins belong to a 
family common to all Plasmodium species character-
ized by the presence of partially conserved domains 
containing six cysteine (Cys) amino acid residues that 
form one to three disulfide bridges, resulting in a spe-
cific tertiary structure [7, 8]. In P. falciparum, this pro-
tein (Pfs48/45) is expressed on the surface membrane of 
gametocytes [9] and is required for male fertility [6]. In 
addition, Pfs48/45 is necessary for production of high 
antibody titers in individuals living in endemic areas 
[10, 11] that can reduce ookinete production and induce 
transmission-blocking activity [12–14]. It is currently 
considered a potential target for development as a trans-
mission-blocking vaccine. As other proteins expressed 
on sexual forms, Pfs48/45 is rich in Cys residues, which 
has made it difficult to express as a recombinant product 
with proper conformation [5, 15]. Pvs48/45, the homol-
ogous protein in P. vivax, was recently expressed in 
Escherichia coli and its immunogenicity was assessed in 
mice and Aotus monkeys. These studies indicated high 
immunogenicity in both animal models and the elicited 
antibodies displayed significant and reproducible trans-
mission-blocking activity in ex vivo P. vivax membrane-
feeding assays (MFA) [9].
Genetic diversity could generate antigenic polymor-
phisms, which in turn could induce changes in criti-
cal epitopes and hamper vaccine efficacy. Successful 
development of an effective transmission-blocking vac-
cine is likely dependent on an assessment of the degree 
of genetic diversity in pvs48/45 among P. vivax parasite 
populations in malaria-endemic locations [16]. Although 
available data indicate a limited Pvs48/45 genetic poly-
morphism on a regional scale [17, 18], knowledge of 
the sequence polymorphism on a broader scale and its 
potential impact on vaccine development is needed. 
Here, a total of 282 pvs48/45 sequences corresponding 
to parasites from eight countries from around the world 
were analysed for gene diversity to assess probable pro-
tein changes that could influence the immunogenicity 
and its vaccine potential.
Methods
Ethics statement
Blood samples used in this study were obtained from 
studies approved by the Institutional Review Board 
(IRB) of the Malaria Vaccine and Drug Development 
Center (MVDC) under the codes CIV-01-042009, CIV 
08-102010 and CIV 009. Samples from volunteers were 
not linked to the identity of the donor. Written informed 
consent was obtained from each volunteer at enrolment. 
All volunteers were adults over 18 years of age.
Origin of Plasmodium vivax samples
The genetic diversity of pvs48/45 was studied among 60 P. 
vivax isolates from endemic regions of Brazil, Colombia 
and Honduras in Latin American (LA). The geographical 
origin of each of the LA isolates analysed in this study is 
listed in Table 1. Brazilian P. vivax isolates (n = 13) were 
obtained from patients attending a tertiary healthcare 
centre in Manaus (Amazonas State) [19]; Colombian 
parasite samples (n =  35) were collected in four differ-
ent malaria-endemic regions described elsewhere [20]; 
Honduran samples (n  =  12) were collected at the Uni-
versity Hospital located in Tegucigalpa, and its origin was 
determined to seven different localities throughout the 
country. Additionally, a total of 222 sequences reported 
to the GenBank and PlasmoDB originally from South 
Korea [17], North Korea [18], India and Indonesia [18], 
Thailand and Vanuatu [21], Mexico, Peru, Thailand and 
Myanmar (Plasmodium vivax Hybrid Selection initiative, 
Broad Institute [22, 23], and reference sequences from 
Brazil, India, Mauritania, and North Korea were used for 
comparison.
Extraction and purification of parasite genomic DNA
Parasite genomic DNA was extracted from filter-paper 
blood spots using 10  % Chelex 100 (Biorad, USA) and 
from EDTA-blood samples using the salting-out method 
[24], and were identified with two-letter codes according 
to the country of origin as follows: Colombia (Co), Bra-
zil (Br) and Honduras (Hn), followed by two numerical 
digits. Subsequently, DNA was purified using the Pure-
Link Genomic DNA Mini Kit (Life Technologies, USA), 
according to the manufacturer’s instructions. DNA sam-
ples were tested by real-time quantitative PCR (qPCR) to 
confirm infection with P. vivax and rule out P. falciparum 
co-infection as previously described [25].
Amplification and sequencing of the Pvs48/45 gene 
in parasite samples from Latin America
Pvs48/45F (5′-GGAATAATTTCGACCACTC-3′) and 
Pvs 48/45R (5′- TCAGAAGTACAACAGGAG-3′) prim-
ers were designed to amplify the Pvs48/45 gene coding 
region (CDS annotation 1357  bp) from the pvs48/45 of 
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Salvador I strain (PlasmoDB Id: PVX_083235). Ampli-
fication was performed in 25  μL reactions containing 
2–4 μL genomic DNA, 500 nM of primers Pvs48/45F and 
Pvs48/45R, and 0.5 units of HotStar HiFidelity Polymer-
ase (QIAGEN, Valencia, CA, USA). Thermal cycling con-
ditions were as follows: initial denaturation for 5 min at 
94 °C, followed by 39 cycles of: 94 °C for 30 s, 55 °C for 
1 min, 72 °C for 2 min, and a final extension step at 72 °C 
for 10 min. Amplification products were analysed by gel 
electrophoresis in 1.2  % agarose gels and purified using 
the High Pure PCR product purification kit, according 
to the manufacturer’s recommendations (Roche Diag-
nostics, Mannheim, Germany). Purified PCR products 
were sequenced using the Big Dye Terminator Kit v3.1 
(Applied Biosystems, Austin, TX, USA) in an ABI-PRISM 
Avant 3100 Automatic Genetic Analyzer (Applied Bio-
systems, Foster City, CA, USA) using primers Pvs48/45F 
and Pvs48/45R. Each purified product was sequenced 
in both directions by a minimum of two independ-
ent sequencing reactions until quality base calling value 
scores >20 (predictive sequencing error rate per base of 
1.00 %) were obtained [26], as assessed with the Sequenc-
ing Analysis Software v.5.3 (Applied Biosystems).
Sequence assembling, alignment and statistical analysis
All sequences were assembled against the Sal I P. vivax 
pvs48/45 sequence reported in PlasmoDB (accession No. 
PVX_083235) using the reference assembler algorithm 
in Geneious 4.8.4 [27] and corrections made by manual 
inspection. The primers sequences were removed before 
the analysis. Consensus sequences were aligned using 
the Geneious alignment algorithm and the alignment 
was used to calculate the number of segregating sites 
(S), singleton sites, singleton variable (SV) sites, parsi-
mony informative (PI) sites, haplotype diversity (Hd), 
nucleotide diversity (π), and the average number of pair-
wise nucleotide differences within the population (K), 
number of synonymous (dS) and non-synonymous (dN) 
substitutions with DnaSP 5.10 package using the Jukes-
Cantor model. DNA polymorphism was analysed with a 
sliding window of 100 bases and a step of 25 bases for a 
haploid genome [28]. To determine the influence of the 
geographical origin of the isolates on nucleotide diversity 
and DNA polymorphism, the same analysis discriminat-
ing between groups of samples from Brazil, Colombia and 
Honduras was performed. Output data were exported 
to Excel to plot overlapping π curves with standardized 
scales for the different groups. Numbers of synonymous 
(dS) and non-synonymous (dN) substitutions were com-
pared by a two-tailed Z test (P < 0.05) using MEGA 6.06 
[29] using the Nei and Gojobori’s method [30] with the 
Jukes-Cantor correction and its standard deviation deter-
mined by 1000 boot-strap replications [31]. Null hypoth-
esis was dS  =  dN, thus indicating that the observed 
polymorphism was neutral.
Phylogenetic and epitope conservation analysis
Tajima’s D test and Fu and Li’s D and F tests using Plas-
modium knowlesi pvs48/45 as an outgroup were per-
formed on DNASP 5.10 to test for the neutral theory of 
evolution. Haplotypes reported in this study were com-
pared to 132 pvs48/45 sequences reported in GenBank 
for South Korea [17], North Korea [18], India and Indo-
nesia [18], and reference sequences from Brazil, India, 
Mauritania, and North Korea and Sal I, same as described 
above, for a total of 252 isolates. In silico translated DNA 
sequences were aligned to the Pfs48/45 3D7 amino acid 
sequence (PFD3D7_1346700) to ensure the localization 
of the single nucleotide polymorphisms (SNPs) in the 
Cys-rich domains (CRD) I, II, and III were epitopes I, II, 
III and V as previously reported [12]. Phylogenetic analy-
sis was performed with the 60 sequences reported in this 
study, and with the 49 sequences reported in GenBank.
Immune epitope mapping
In order to determine the presence of linear B cell 
epitopes in the Pvs48/45 protein sequence and the pos-
sible influence of the SNP in the predicted epitopes, an 
in silico analysis of the entire sequence was performed. 
Epitopes were predicted based on hydrophilicity, acces-
sibility, polarity, flexibility estimation, combined with 
secondary structure analysis (Kolaskar-Tongaonkar anti-
genicity prediction methods) [32].
Molecular modelling of the 3D structure
Structural models of Pvs48/45 domains were built by 
using homology-based modelling. The known 3D struc-
tures of homologous proteins Pf12 from P. falciparum 
Table 1 Origin of  Latin American isolates used for   
pvs48/45 sequencing
Country Department Locality N
Brazil Amazonas Manaus 14
Honduras El Paraiso Moroceli 1
Olancho Catacamas 2
Juticalpa 1
Francisco Morazan Talanga 2
Tegucigalpa (CMDC) 2
Gracias a Dios Pto. Lempira 1
Wampusirpi 2
Colombia Cordoba Tierralta 10
Nariño Tumaco 10
Valle del Cauca Buenaventura 8
Choco Quibdó 7
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[33] and the immunodominant surface antigen from 
Toxoplasma gondii (Protein Data Bank IDs: 2YMO:A and 
1KZQ:A) were used as templates. Sequence alignments 
were obtained by using a HHpred server [34], ClustalW 
program [35] and manual adjustment. Structural mod-
els were built using the HOMOLOGY module of Insight 
II program [36]. Resulting structures were subjected to 
energy minimization using the procedure implemented 
in the Discovery sub-routine of Insight II.
Results
Genetic polymorphism and amino acid changes
Results of the qPCR assay indicated that all samples were 
specific for P. vivax infections. PCR amplification of 
the Pvs48/45 gene-coding region showed a single band 
of  ~1.3  kb in all samples, indicating an absence of size 
polymorphism. Comparison of the nucleotide sequences 
against the pvs48/45 reference sequence (Sal I) showed 
that SNPs occurred at 15 positions. Nine of these muta-
tions resulted in amino acid changes (non-synonymous 
substitutions) at positions E35K, Y196H, H211N, K250N, 
D335Y, E353Q, A376T, K390T, and K418R (Fig. 1a), while 
the remaining six had no amino acid variations (syn-
onymous substitutions). Of the nine sites, two (H211N, 
K250N) were found worldwide, four in Asian isolates 
(E35K, D335Y, A376T, K418R), while the remaining three 
were country-specific (Y196H Thailand, K390T Peru, 
E353Q in Mexico, Peru and Colombia).
Pvs48/45 gene haplotypes
Based on sequence analysis, the pvs48/45 sequences were 
classified into seven haplotypes (haplotypes I–VII), in 
which three resulted from trimorphic polymorphisms, 
two from dimorphic polymorphisms, and one from a sin-
gle polymorphism. None of these substitutions was com-
mon in all isolates. The amino acid substitution E353Q 
was found in haplotypes I–IV. The K250N substitution 
was found in haplotypes I, II, IV, V, and VII, while the 
H211N amino acid substitution was found in haplotypes 
I and V. Amino acid substitutions A108T, P264H, N324S, 
and K370N were only found in haplotypes IV, VI, VII, 
and V, respectively (Table 2).
Global diversity of pvs48/45
Comparison of pvs48/45 polymorphic positions found in 
LA countries (Brazil, Colombia and Honduras) with the 
nine polymorphic positions reported for South Korea, 
North Korea, India and Indonesia showed a set of amino 
acid substitutions exclusively present among LA isolates. 
This set contained the substitution E353Q, which is the 
most frequent among LA isolates (41.9 %), together with 
the less frequent substitutions T108A (2.3  %), P264H 
(2.3 %), N324S (2.3 %), and K370N (2.3 %). On the con-
trary, D335Y, which is highly conserved among Asian 
isolates (95.5  %), was not detected among LA isolates. 
Amino acid variations H211N and K250N are found 
in both Asian and LA isolates. These two substitutions, 
highly conserved among Asian isolates (98.5 and 100 %, 
respectively) were only found in 18.6 and 39.5  % of P. 
vivax LA isolates, respectively. Other substitutions previ-
ously reported for Asian isolates [17, 18]: K26R (1.5 %), 
E35K (62.1  %), A367T (95.5  %), I380T (19.7  %), K418R 
(95.5 %) were not found in the present study. As a result, 
the number of haplotypes for worldwide samples was 
18 (Table  3). There was variation of haplotype diversity 
geographically: low in North Korea, Peru and Mexico, 
and higher in Myanmar and Colombia. Nucleotide 
diversity (π) was 0.00173 for worldwide samples, rang-
ing between 0.00058 and 0.00216 (Table 3). In Myanmar 
and Colombia π was relatively high, whereas it was low 
in Mexico, Peru and South Korea. A sliding window plot 
of π revealed a peak at nucleotide positions 1000–1160 
in the CRD-3 region where four of the nine amino acid 
changes observed in Pvs48/45 occurred (Fig. 1b). The π 
of Pv48/45 in worldwide samples was at least one order 
of magnitude lower than that of known blood-stage anti-
gen genes, such as pvmsp1, pvmsp3a and pvdbp (Fig. 2).
Geographic distribution of vs48/45 haplotypes among LA 
isolates
The wild-type (Sal I-like) haplotype predominated among 
Brazilian (92  %), Peruvian (90  %), Mexican (87  %), and 
Honduran (71  %) isolates, however in Colombian iso-
lates, it was the second-most frequent haplotype (24 %). 
Colombian isolates showed a major presence of hap-
lotype I (52  %), which was less frequent in Honduran 
isolates (14 %), and not detected among Brazilian, Peru-
vian and Mexican samples. Haplotype VI, the most fre-
quent in Myanmar and Thailand, was found only among 
Colombian isolates, whereas haplotype VII was only pre-
sent in Colombia isolates. Colombia showed the greatest 
haplotype diversity (0.841 ±  0.024) with eight non-Sal I 
haplotypes circulating in the country.
Mapping of immune epitopes
A total of 12 linear epitopes were identified in regions 1, 
5, 6, and 12, displaying greater algorithmic scores predic-
tive of putative antigenic peptides (Table 4). A high score 
indicates maximum probability of immunogenicity in the 
host. Four of the 12 predicted regions contained poly-
morphic amino acids, however mutations were located in 
less antigenic epitopes. These substitutions did not affect 
the epitope prediction, and had limited impact on the 
calculated antigenic score (e.g., region 7, 1.154 vs 1.153).
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SNPs location on 3D Pvs48/45 domain structure
A 3D model of Pvs48/45 was generated to understand 
the potential structure–function relationship of the 
nine polymorphic amino acids under balancing selec-
tion. SNPs were located in different regions of Pvs48/45: 
H211N (18.6  %) was in an intervening region between 
Fig. 1 Nucleotide changes found and nucleotide diversity. a Structural architecture of Pvs48/45 reported by van Dijk [6]. Cysteine residues are 
depicted as small black bars under the three cysteine‑rich domains (CRD), non‑synonymous substitutions are shown by solid arrows, whereas syn‑
onymous substitutions by dashed arrows. b Sliding‑window analysis of nucleotide diversity (π) along the Pvs48/45 gene using a length of 100 sites 
and a step‑size of 25 sites
Table 2 Amino acid changes found in the seven pvs48/45 haplotypes in Latin American isolates
Amino acid position n Frequency (%)
108 211 250 264 324 353 370
Sal I T H K P N E K 68 25.1
I – N N – – Q – 35 12.9
II – – N – – Q – 9 3.3
III – – – – – Q – 2 0.7
IV A – N – – Q – 4 1.5
V – N N – – Q N 83 30.6
VI – – – H – – – 64 23.6
VII – – N – S – – 6 2.2
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domains 1 and 2; K250N (39.5 %) was located in domain 
CRD-2, which is not considered a six-cys domain; and 
E353Q (41.9  %), A376T (50.7  %), K390T (1.1  %), and 
K418R (51.7 %) in domain CRD-3, which is the nearest to 
the trans-membrane region (Fig. 3). Mapping of the SNPs 
that led to amino acid substitutions onto the Pvs48/45 3D 
model domains showed that these residues are located in 
the loop regions.
Discussion
This study showed a limited pvs48/45 genetic diversity in 
a total of 282 P. vivax isolates worldwide. Only 18 amino 
acid substitutions were found within the entire protein 
sequence of an estimated 450 amino acid residues. Plas-
modium vivax sequences corresponded to isolates from 
nine distant countries in three continents. Two pvs48/45 
haplotypes were found to be shared by Asian and LA 
Table 3 Estimates of DNA sequence polymorphism and tests of neutrality for pvs48/45
SV singleton variable, PI parsimony informative, K average number of pair-wise differences, H number of haplotypes, Hd haplotype diversity, π observed average pair-
wise nucleotide diversity, dN number of non-synonymous substitutions, dS number of synonymous substitutions
Country Total isolates SV sites PI sites # Mutations K H Hd ± SD π ± SD dN dS Reference
Mexico 15 0 2 2 0.441 2 0.221 ± 0.121 0.00033 ± 0.00033 0.00042 0.00000 This study
Honduras 12 3 2 5 1.128 4 0.445 ± 0.170 0.00123 ± 0.00094 0.00136 0.00077 This study
Colombia 60 3 4 7 1.929 9 0.841 ± 0.024 0.00188 ± 0.00073 0.00185 0.002 This study
Peru 24 1 2 3 0.372 3 0.218 ± 0.103 0.00034 ± 0.00046 0.00045 0.00000 This study
Brazil 13 2 1 3 0.59 4 0.526 ± 0.153 0.00058 ± 0.00062 0.00019 0.00194 This study
Latin America 124 3 5 8 1.228 11 0.610 ± 0.047 0.00168 ± 0.00087 0.00176 0.00151 This study
Myanmar 8 2 5 7 2.722 5 0.889 ± 0.071 0.00216 ± 0.00110 0.00282 0.0000 This study
Thailand 18 5 4 9 1.392 5 0.484 ± 0.138 0.00116 ± 0.00101 0.00103 0.00085 This study
South Korea 86 0 2 2 0.716 3 0.611 ± 0.026 0.00053 ± 0.00004 0.00069 0.00000 [17]
North Korea 46 2 7 9 1.987 5 0.0018 ± 0.042 0.00147 ± 0.00069 0.00029 0.00186 [18]
Worldwide 282 7 5 12 1.047 15 0.686 ± 0.00149 0.00173 ± 0.00149 0.00188 0.00149 This study
Fig. 2 Distribution of pvs48/45 haplotypes. Geographic distribution of pvs48/45 haplotypes is shown for Mexico, Honduras, Brazil, Colombia, Myan‑
mar, Thailand, South Korea, and North Korea. Haplotypes I–VII are shown in different colours
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parasites, with a strong geographical allele clustering. 
Recent studies on the diversity of pvs48/45 among P. 
vivax isolates circulating in the Korean peninsula, China 
and Thailand showed low levels of genetic diversity [17, 
18, 21, 37]; likewise, Brazilian isolates showed almost no 
variation when compared to the Sal I reference strain 
(PVX_083235), originally from El Salvador.
Interestingly, Korean, Colombian and Honduran 
isolates displayed limited sequence polymorphism. 
Pvs48/45 nucleotide and amino acid substitutions in iso-
lates from Korea were found at pre-CRD (E35K), CRD-2 
(H211N and K250N) and CRD-3 (D335Y, A376T, I380T, 
K418R). Pvs48/45 was more conserved in the Korean 
populations where nucleotide diversity varied from 
0.00053 [17] to 0.00147 [17, 18], and the haplotypes V 
was unique for these populations. Plasmodium vivax was 
recently re-introduced into the peninsula of Korea with a 
rapid spread pattern, suggestive of a high genetic diver-
sity [38]. This could explain the greater pvs48/45 variabil-
ity observed in Korean isolates as compared to isolates 
from Honduras and Mexico, and the almost absent vari-
ability among Brazilian isolates Despite the variability in 
the Korean isolates, globally, Pvs48/45 remains a highly 
conserved antigen compared to other transmission-
blocking vaccine candidates.
Results are in agreement with previous observations 
that transmission-blocking vaccine candidate antigens 
Pvs25, Pvs28, Pvs48/45, and PvWARP showed limited 
sequence polymorphisms [18]. More importantly, the 
limited polymorphism found here does not appear to 
affect the immunogenicity of predicted epitopes as only 
three of nine amino acid substitutions in isolates from 
Colombia and Honduras were located at CRD2 (H211N 
and K250N) and CRD3 (E353Q). No substitutions were 
observed in CRD1, in agreement with reports for Korean 
isolates and for P. falciparum in Kenyan, Thai, Indian, and 
Venezuelan isolates [39, 40]. However, further studies 
are required to confirm the role of these B cell epitopes 
and to identify T cell epitopes in defining the potential of 
Pvs48/45 as a transmission-blocking vaccine candidate.
Table 4 Potential antigenic determinants for the Pvs48/45
a Italics AA indicates Cysteine residues, whereas Bold italics AA represent the location of polymorphic sites
# Antigenic region AA start AA end Length Score Polymorphism Sequencea
1 4 19 16 1.235 None RQLANLLLVLSLLRGI
2 46 64 19 1.083 None GFKCNFSSKGVHNLEPILT
3 66 90 25 1.197 None KRSLVCSIYSYFIYDKIKLTIPKKI
4 99 109 11 1.129 None PEKCFQTVYTN
5 165 189 25 1.206 None ISNVKGRVALVQVNVLKYPHKITSI
6 220 237 18 1.228 None GELVVLACEKVDDKCFKK
7 242 304 63 1.154 K250N SPLSLYKSKKIVYHKNLSIFKAPVYVKSADVTAECSCNVDSTIYTLSLKPVYT 
KKLIHGCNFS
8 326 341 16 1.138 D335Y QITCSIELVDTSYNHL
9 347 361 15 1.167 E353Q PGEVLPECFFQVYQR
10 366 377 12 1.141 A376T LEPSKIVYLDAQ
11 394 404 11 1.152 None IVKIFGLVGSI
12 422 447 26 1.255 None YMSVKIAAGYFGFLAKIFILLIVLLL
Fig. 3 A ribbon representation of 3D models of the Pvs48/45 domains. Space‑filling representation of amino‑acid side chains (red, blue and yellow 
balls) denotes the locations of the non‑synonymous amino acid substitutions in the three cysteine‑rich domains (CRD)
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Pvs48/45 Cys domains are important for proper con-
formation of immune epitopes [8, 45]. In Pfs48/45, four 
epitopes designated epitope V (CRD1), epitope IIb 
(CRD2), epitope III (CRD2), and epitope I (CRD3) have 
been described previously [8]. The N-terminal CRD2 
and CRD3 epitopes appear to be transmission-block-
ing targets as specific monoclonal antibodies to these 
regions have demonstrated an ability to prevent para-
site fertilization, and consequently mosquito infection 
[12, 46].
Substitutions H211N and K250N are predicted to be 
located in loop regions [18], which could serve as poten-
tial vaccine targets. Interestingly, no amino acid substitu-
tions were found in any of the Cys residues of Pvs48/45 in 
the present study, which are critical for proper presenta-
tion of the transmission-blocking epitopes [12]. However, 
an amino acid substitution (E353Q) was found next to a 
Cys residue reported to be involved in a disulfide bond. 
The influence of this variation on the formation of the 
disulfide bridge is yet to be explored.
Although parasite antigen diversity has been explained 
in part by immune pressure on the parasite [41–43], 
it does not appear to apply to Pvs48/45 as the protein 
is highly immunogenic, and it is expressed during the 
entire gametocyte maturation process. For P. vivax sex-
ual antigens the exposure to the immune system could 
be longer than in P. falciparum due to the early appear-
ance of P. vivax gametocytes in circulation [44]. However 
it does not appear to apply to Pvs48/45 as the protein 
is conserved and highly immunogenic under natural 
conditions.
Transmission-blocking vaccines have been considered 
a promising strategy/tool for malaria control/elimina-
tion. In P. vivax malaria it has been observed that game-
tocytogenesis occurs earlier than in P. falciparum and 
remains active even in asymptomatic carriers [44]. Con-
sequently, malaria transmission to mosquitoes is likely to 
be more efficient, and thus, transmission-blocking vac-
cines would have a greater impact [47].
Conclusions
There is limited sequence polymorphism in pvs48/45 
with noted geographical clustering among Asian and 
American isolates. The low genetic diversity of the pro-
tein does not influence the predicted antigenicity or 
protein structure and, therefore, supports its further 
development as a transmission-blocking vaccine candi-
date with widespread global potential.
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